Search

A new nanodevice based on gold nanoparticles (AuNPs) capped with poly(diethylvinylphosphonate) (PDEVP) has been synthesized, showing interesting photophysical and thermoresponsive properties. The synthesis involves a properly designed Yttriocene catalyst coordinating the vinyl-lutidine (VL) initiator active in diethyl vinyl phosphonate polymerization. The unsaturated PDEVP chain ending was thioacetylated, deacetylated, and reacted with tetrachloroauric acid and sodium borohydride to form PDEVP-VL-capped AuNPs. The NMR, UV–Vis, and ESI-MS characterization of the metal nanoparticles confirmed the formation of the synthetic intermediates and the expected colloidal systems. AuNPs of subnanometric size were determined by WAXD and UV–Vis analysis. UV–Vis and fluorescence analysis confirmed the effective anchoring of the thiolated PDEVP to AuNPs. The formation of 50–200 nm globular structures was assessed by SEM and AFM microscopy in solid state and confirmed by DLS in aqueous dispersion. Hydrodynamic radius studies showed colloidal contraction with temperature, demonstrating thermoresponsive behavior. These properties suggest potential biomedical applications for the photoablation of malignant cells or controlled drug delivery induced by light or heat for the novel PDEVP-capped AuNP systems. [ABSTRACT FROM AUTHOR]

Cannabigerol's (CBG) therapeutic effects are limited by its poor water solubility and low dissolution rate. To improve these properties, supercritical CO2-assisted atomization (SAA) was applied to produce coprecipitates, i.e., CBG nanoparticles coprecipitated in polyvinylpyrrolidone (PVP) microparticles. The experiments were performed by varying the CBG/PVP mass ratio (R) and the overall concentration of solutes CBG+PVP to study the influence of these parameters on particle morphology, particle size, and size distribution. Periodic dynamic light scattering (DLS) analysis was performed at regular time intervals to measure the size of CBG nanoparticles in PVP microparticles. It showed that CBG nanoparticles down to 105 nm were successfully produced through SAA. Dissolution tests were used to verify that a reduction of CBG particle size significantly increased its dissolution rate. In the liquid medium adopted, untreated CBG powder was released in 210 min, whereas CBG nanoparticles of 105 nm were completely dissolved in only 15 min. [ABSTRACT FROM AUTHOR]

Theranostics is a growing field that matches diagnostics and therapeutics. In this approach, drugs and techniques are uniquely coupled to diagnose and treat medical conditions synergically or sequentially. By integrating diagnostic and treatment functions in a single platform, the aim of theranostics is to improve precision medicine by tailoring treatments based on real-time information. In this context, lipid-based nanocarriers have attracted great scientific attention due to their biodegradability, biocompatibility, and targeting capabilities. The present review highlights the latest research advances in the field of lipid-based nanocarriers for cancer theranostics, exploring several ways of improving in vivo performance and addressing associated challenges. These nanocarriers have significant potential to create new perspectives in the field of nanomedicine and offer promise for a significant step towards more personalized and precise medicine, reducing side effects and improving clinical outcomes for patients. This review also presents the actual barriers to and the possible challenges in the use of nanoparticles in the theranostic field, such as regulatory hurdles, high costs, and technological integration. Addressing these issues through a multidisciplinary and collaborative approach among institutions could be essential for advancing lipid nanocarriers in the theranostic field. Such collaborations can leverage diverse expertise and resources, fostering innovation and overcoming the complex challenges associated with clinical translation. This approach will be crucial for realizing the full potential of lipid-based nanocarriers in precision medicine. [ABSTRACT FROM AUTHOR]

The text discusses the use of nanosomes in precision nanomedicine to deliver drugs to specific cells or tissues, improving efficacy and safety. Various types of nanosomes, such as niosomes and transfersomes, are explored for drug delivery applications. Researchers have developed innovative methods and materials, like Fe-N-C nanozymes and polydopamine, to enhance drug delivery and treatment outcomes. The field of nanomedicine is rapidly expanding, with a focus on personalized medicine and reducing side effects for patients worldwide. [Extracted from the article]